_×
Human MARK3 Gene cDNA Clone (full-length ORF Clone)
  0 products, total $0.+86-400-890-9989      Login |  Register 中文한국어

Browse By Molecule:

Your Position: Home > Gene Products > Human cDNA Clones > Human MARK3 Gene cDNA Clone (full-length ORF Clone)

Human MARK3 Gene cDNA Clone (full-length ORF Clone)

Catalog Vector (Price) Quantity In Stock Operation
HG12181-G





  YES

*  pCMV vectors are ALL featured with a CMV promoter and a hygromycin-resistance (hygro) gene. These plasmids can be used directly in mammalian cell expression. Learn more about pCMV vectors.
    Notice: Additional handling time(2-3 weeks) may be required if a pCMV vector is selected.

Antibody Production Services

MARK3 cDNA Clone Datasheet

 

MARK3 cDNA Clone Product Information

Gene Bank Ref.ID: BC024773

cDNA Size:

2190

Gene Synonym:

KP78; CTAK1; PAR1A; Par-1a;MARK3

Source: Human

MARK3 cDNA Clone Description

cDNA Description:

ORF Clone of Homo sapiens MAP/microtubule affinity-regulating kinase 3 DNA.

Vector: Cloning Vector: pGEM-T Vector

Expression Vectors: pCMV/hygro, pCMV/hygro-Myc, pCMV/hygro-His, pCMV/hygro-HA, pCMV/hygro-FLAG

Sequence Description: Identical with the Gene Bank Ref.ID sequence.

MARK3 cDNA Clone Shipping

  1. 5-10μg Plasmid DNA is shipped on Whatman FTA elute card (Cat. No.: WB120410) at room temperature.
  2. It would take 7-14 days for delivery typically. For bulk orders, additional 1-2 weeks would be needed.

MARK3 cDNA Clone Usage Protocol

  1. Cut along the circle edge of the spot (arrow points to) to get the filter paper.
  2. Transfer the filter paper to a 1.5ml microfuge tube containing 150-200 μl of sterile H2O Ensure the filter is completely immersed in the H2O Briefly centrifuge the tube for 10 seconds.
  3. Incubate the tube at 95℃ for 15-30 min.
  4. At the end of the incubation pulse vortex, or gently tap the tube.
  5. Briefly centrifuge for 30 seconds, to separate the matrix from the elute. The elute now contains the purified DNA.

MARK3 cDNA Clone Sequence and Quality Control

Sequence:

1        ATGTCCACTA GGACCCCATT GCCAACGGTG AATGAACGAG ACACTGAAAA CCACACGTCA
61       CATGGAGATG GGCGTCAAGA AGTTACCTCT CGTACCAGCC GCTCAGGAGC TCGGTGTAGA
121      AACTCTATAG CCTCCTGTGC AGATGAACAA CCTCACATCG GAAACTACAG ACTGTTGAAA
181      ACAATCGGCA AGGGGAATTT TGCAAAAGTA AAATTGGCAA GACATATCCT TACAGGCAGA
241      GAGGTTGCAA TAAAAATAAT TGACAAAACT CAGTTGAATC CAACAAGTCT ACAAAAGCTC
301      TTCAGAGAAG TAAGAATAAT GAAGATTTTA AATCATCCCA ATATAGTGAA GTTATTCGAA
361      GTCATTGAAA CTGAAAAAAC ACTCTACCTA ATCATGGAAT ATGCAAGTGG AGGTGAAGTA
421      TTTGACTATT TGGTTGCACA TGGCAGGATG AAGGAAAAAG AAGCAAGATC TAAATTTAGA
481      CAGATTGTGT CTGCAGTTCA ATACTGCCAT CAGAAACGGA TCGTACATCG AGACCTCAAG
541      GCTGAAAATC TATTGTTAGA TGCCGATATG AACATTAAAA TAGCAGATTT CGGTTTTAGC
601      AATGAATTTA CTGTTGGCGG TAAACTCGAC ACGTTTTGTG GCAGTCCTCC ATACGCAGCA
661      CCTGAGCTCT TCCAGGGCAA GAAATATGAC GGGCCAGAAG TGGATGTGTG GAGTCTGGGG
721      GTCATTTTAT ACACACTAGT CAGTGGCTCA CTTCCCTTTG ATGGGCAAAA CCTAAAGGAA
781      CTGAGAGAGA GAGTATTAAG AGGGAAATAC AGAATTCCCT TCTACATGTC TACAGACTGT
841      GAAAACCTTC TCAAACGTTT CCTGGTGCTA AATCCAATTA AACGCGGCAC TCTAGAGCAA
901      ATCATGAAGG ACAGGTGGAT CAATGCAGGG CATGAAGAAG ATGAACTCAA ACCATTTGTT
961      GAACCAGAGC TAGACATCTC AGACCAAAAA AGAATAGATA TTATGGTGGG AATGGGATAT
1021     TCACAAGAAG AAATTCAAGA ATCTCTTAGT AAGATGAAAT ACGATGAAAT CACAGCTACA
1081     TATTTGTTAT TGGGGAGAAA ATCTTCAGAG CTGGATGCTA GTGATTCCAG TTCTAGCAGC
1141     AATCTTTCAC TTGCTAAGGT TAGGCCGAGC AGTGATCTCA ACAACAGTAC TGGCCAGTCT
1201     CCTCACCACA AAGTGCAGAG AAGTGTTTCT TCAAGCCAAA AGCAAAGACG CTACAGTGAC
1261     CATGCTGGAC CAGCTATTCC TTCTGTTGTG GCGTATCCGA AAAGGAGTCA GACCAGCACT
1321     GCAGATAGTG ACCTCAAAGA AGATGGAATT TCCTCCCGGA AATCAAGTGG CAGTGCTGTT
1381     GGAGGAAAGG GAATTGCTCC AGCCAGTCCC ATGCTTGGGA ATGCAAGTAA TCCTAATAAG
1441     GCGGATATTC CTGAACGCAA GAAAAGCTCC ACTGTCCCTA GTAGTAACAC AGCATCTGGT
1501     GGAATGACAC GACGAAATAC TTATGTTTGC AGTGAGAGAA CTACAGCTGA TAGACACTCA
1561     GTGATTCAGA ATGGCAAAGA AAACAGCACT ATTCCTGATC AGAGAACTCC AGTTGCTTCA
1621     ACACACAGTA TCAGTAGTGC AGCCACCCCA GATCGAATCC GCTTCCCAAG AGGCACTGCC
1681     AGTCGTAGCA CTTTCCACGG CCAGCCCCGG GAACGGCGAA CCGCAACATA TAATGGCCCT
1741     CCTGCCTCTC CCAGCCTGTC CCATGAAGCC ACACCATTGT CCCAGACTCG AAGCCGAGGC
1801     TCCACTAATC TCTTTAGTAA ATTAACTTCA AAACTCACAA GGAGTCGCAA TGTATCTGCT
1861     GAGCAAAAAG ATGAAAACAA AGAAGCAAAG CCTCGATCCC TACGCTTCAC CTGGAGCATG
1921     AAAACCACTA GTTCAATGGA TCCCGGGGAC ATGATGCGGG AAATCCGCAA AGTGTTGGAC
1981     GCCAATAACT GCGACTATGA GCAGAGGGAG CGCTTCTTGC TCTTCTGCGT CCACGGAGAT
2041     GGGCACGCGG AGAACCTCGT GCAGTGGGAA ATGGAAGTGT GCAAGCTGCC AAGACTGTCT
2101     CTGAACGGGG TCCGGTTTAA GCGGATATCG GGGACATCCA TAGCCTTCAA AAATATTGCT
2161     TCCAAAATTG CCAATGAGCT AAAGCTGTAA

 

Quality Control:cDNA sequencing results is available upon request.

 

 

MARK3 (C-TAK1) related areas, pathways, and other information

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"